姓名：张琪 性别：女 职称：研究员
学院：附属第三医院 最后学历：博士
主要研究方向：干细胞的基础研究与临床转化应用 ；肝癌微环境、肿瘤生物治疗
医疗专长:
肝胆外科常见疾病诊治、肿瘤免疫细胞治疗
获奖情况:
获全国百篇优秀博士学位论文奖励、新世纪优秀人才支持计划
论 著:
1）Zhang Q, Chen G, Liu X, Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res. 2007 Feb;17(2):89-99.
2）Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, Tai Y, Zhang Q※, Chen G. Hepatocellular Carcinoma-Associated Fibroblasts Trigger NK Cell Dysfunction via PGE2 and IDO. Cancer Lett. 2011 Dec 17. [Epub ahead of print]
3）Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q※, Chen GH. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One. 2011;6(9):e25295.
4）Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, Zhang Q※, Chen G. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett. 2011;307(1):93-103.
5）Wang GY, Yang Y, Li H, Zhang J, Li MR, Zhang Q※, Chen GH. Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4(+) CD25(+) Foxp3(+) regulatory T cell expansion. Hepatol Res. 2012 ;42(2):192-202
6）ZHANG Ying-cai, ZHANG Qi※, LI Hua, ZHANG Jian, WANG Gen-shu, XU Chi, YI Shu-hong, YI Hui-min, CAI Chang-jie, LU Min-qiang, YANG Yang , CHEN Gui-hua. Prognostic factors for late mortality after liver transplantation for benign end-stage liver disease . Chin Med J (Engl). 2011,124:4229-35.
7）Lei J, Wang Z, Hui D, Yu W, Zhou D, Xia W, Chen C, Zhang Q, Wang Z, Zhang Q※, Xiang AP. Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity. Cell Immunol. 2011;271(1):147-56. Cell Immunol. 2011;271(1):147-56
8）ZHANG Qi, YANG Yang, ZHANG Jian, WANG Guo-ying, LIU Wei, QIU Dong-bo, HEI Zi-qing, YING Qi-long , CHEN Gui-hua. Efficient derivation of functional hepatocytes from mouse induced pluripotent stem cells by a combination of cytokines and sodium butyrate . Chin Med J (Engl). 2011,124:3786-93.
9）Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D, Wang W, Cui Z, Liu Y, Liu C, Jiang M, Fang G, Liu X, Wu M, Qian Q. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combing with endostatin gene. Cancer Res. 2004,64(15):5390-7.
10）Zhang Q, Chen G, Wang X, Peng L, Liu C, Yang Y, Su C, Wu H, Li L, Liu X, Wu M & Qian Q . Increased Safety with Preserved Antitumoral Efficacy on Hepatocellular Carcinoma with Dual-regulated Oncolytic Adenovirus. Clinical Cancer Research 2006;12(21), 6523-6531.
11）Jiang M, Shi W, Zhang Q (cofirst author), Wang X, Guo M, Cui Z, Su Ch, Yang Q, Li Y, Sham J, Liu X, Wu M, and Qian Q. Gene Therapy for Her2 over-expression cancers using adenovirus mediated full-length anti-Her2 antibody. Clinical Cancer Research 2006;12(20):6179-85